Jade Biosciences, Inc.
For the period ended Jun 30, 2026. Filed Aug 10, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except share and per share amounts)
| Three Months EndedJune 30, 2026 | Three Months EndedJune 30, 2025 | Six Months EndedJune 30, 2026 | Six Months EndedJune 30, 2025 | |
|---|---|---|---|---|
| Operating expenses: | ||||
| Research and development(1) | $50,065 | $22,547 | $86,118 | $42,570 |
| General and administrative(2) | 8,851 | 5,231 | 16,243 | 8,592 |
| Total operating expenses | 58,916 | 27,778 | 102,361 | 51,162 |
| Loss from operations | (58,916) | (27,778) | (102,361) | (51,162) |
| Other income (expense): | ||||
| Interest income | 3,228 | 1,828 | 6,330 | 2,443 |
| Change in fair value of Convertible Notes payable(3) | — | (6,184) | — | (21,584) |
| Other expense | (62) | — | (71) | — |
| Total other income (expense), net | 3,166 | (4,356) | 6,259 | (19,141) |
| Net loss before income tax expense | (55,750) | (32,134) | (96,102) | (70,303) |
| Income tax expense | (15) | — | (31) | — |
| Net loss | $(55,765) | $(32,134) | $(96,133) | $(70,303) |
| Other comprehensive loss: | ||||
| Currency translation adjustment | (73) | (24) | (71) | (24) |
| Unrealized loss on investments | (245) | — | (718) | — |
| Comprehensive loss | $(56,083) | $(32,158) | $(96,922) | $(70,327) |
| Net loss per share attributable to common stockholders, basic and diluted | $(0.76) | $(0.86) | $(1.33) | $(3.45) |
| Net loss per share attributable to Series A non-voting convertible preferred stockholders, basic and diluted | $(756.93) | $(863.46) | $(1,334.34) | $(3,450.78) |
| Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted | 61,050,775 | 28,431,158 | 59,423,013 | 15,932,206 |
| Weighted-average shares used in computing net loss per share attributable to Series A non-voting convertible preferred stockholders, basic and diluted | 12,622 | 8,781 | 12,622 | 4,439 |
(1)Includes related party amounts of $13.0 million and $17.3 million for the three and six months ended June 30, 2026, respectively, and $3.9 million and $11.7 million for thethree and six months ended June 30, 2025, respectively (see Note 10).
(2)Includesno related party amount for thethree months ended June 30, 2026 and $0.2 million for thesix months ended June 30, 2026. Includes related party amounts of $0.1 million for each of thethree and six months ended June 30, 2025, respectively (see Note 10).
(3)Includesno related party amounts for thethree and six months ended June 30, 2026 and $1.3 million and $4.6 million for thethree and six months ended June 30, 2025, respectively (see Note 6).
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.